Cosmo Pharmaceuticals N.V./€COPN
06:30
10:10
13:45
17:25
21:00
1D1W1MYTD1Y5YMAX
About Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company headquartered in Dublin, Ireland, with a focus on developing and manufacturing treatments for gastrointestinal diseases, specifically targeting the large intestine. The company's core products include therapies for ulcerative colitis, colon infections, and related areas. Cosmo's notable products, such as Lialda/Mezavant and Eleview, highlight its focus on advanced treatments that enhance colonic drug delivery and endoscopic visualization. The company has strategically concentrated its research and development to specialize in its therapeutic areas, leveraging its proprietary Methacrylate-Copolymer technology. Cosmo Pharmaceuticals also engages in partnerships to extend its market reach and continues to expand its influence globally through strategic collaborations and licensing agreements.
Ticker
€COPN
Sector
Primary listing
XGAT
Employees
332
Headquarters
Dublin, Ireland
Website
COPN Metrics
BasicAdvanced
€1.7B
28.62
€3.67
1.29
€2.05
1.95%
Price and volume
Market cap
€1.7B
Beta
1.29
52-week high
€116.00
52-week low
€44.36
Average daily volume
10K
Dividend rate
€2.05
Financial strength
Current ratio
3.843
Quick ratio
3.589
Long term debt to equity
0.416
Total debt to equity
0.578
Dividend payout ratio (TTM)
94.36%
Interest coverage (TTM)
763.58%
Profitability
EBITDA (TTM)
80.454
Gross margin (TTM)
73.79%
Net profit margin (TTM)
32.91%
Operating margin (TTM)
37.70%
Effective tax rate (TTM)
16.87%
Revenue per employee (TTM)
€550,000
Management effectiveness
Return on assets (TTM)
6.88%
Return on equity (TTM)
12.34%
Valuation
Price to earnings (TTM)
28.62
Price to revenue (TTM)
9.385
Price to book
3.37
Price to tangible book (TTM)
14.49
Price to free cash flow (TTM)
25.621
Free cash flow yield (TTM)
3.90%
Free cash flow per share (TTM)
4.098
Dividend yield (TTM)
1.95%
Forward dividend yield
1.95%
Growth
Revenue change (TTM)
-1.66%
Earnings per share change (TTM)
0.09%
3-year revenue growth (CAGR)
32.61%
10-year revenue growth (CAGR)
12.03%
3-year earnings per share growth (CAGR)
23.18%
10-year earnings per share growth (CAGR)
-13.78%
3-year dividend per share growth (CAGR)
29.22%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cosmo Pharmaceuticals N.V. stock?
Cosmo Pharmaceuticals N.V. (COPN) has a market cap of €1.7B as of December 18, 2025.
What is the P/E ratio for Cosmo Pharmaceuticals N.V. stock?
The price to earnings (P/E) ratio for Cosmo Pharmaceuticals N.V. (COPN) stock is 28.62 as of December 18, 2025.
Does Cosmo Pharmaceuticals N.V. stock pay dividends?
Yes, the Cosmo Pharmaceuticals N.V. (COPN) stock pays dividends to shareholders. As of December 18, 2025, the dividend rate is €2.05 and the yield is 1.95%. Cosmo Pharmaceuticals N.V. has a payout ratio of 94.36% on a trailing twelve-month basis.
When is the next Cosmo Pharmaceuticals N.V. dividend payment date?
The next Cosmo Pharmaceuticals N.V. (COPN) dividend payment date is unconfirmed.
What is the beta indicator for Cosmo Pharmaceuticals N.V.?
Cosmo Pharmaceuticals N.V. (COPN) has a beta rating of 1.29. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.